Please use this identifier to cite or link to this item:
Title: Arnicolide D, from the herb centipeda minima, is a therapeutic candidate against nasopharyngeal carcinoma
Authors: Liu, R 
Chan, BD 
Mok, DKW 
Lee, CS
Tai, WCS 
Chen, SB 
Keywords: Arnicolide D
Cell cycle arrest
Apoptosis induction
Issue Date: 2019
Publisher: Molecular Diversity Preservation International
Source: Molecules, 2 May 2019, v. 24, no. 10, 1908, p. 1-15 How to cite?
Journal: Molecules 
Abstract: Nasopharyngeal carcinoma (NPC) is a high morbidity and mortality cancer with an obvious racial and geographic bias, particularly endemic to Southeast China. Our previous studies demonstrated that Centipeda minima extract (CME) exhibited anti-cancer effects in human NPC cell lines. Arnicolide C and arnicolide D are sesquiterpene lactones isolated from Centipeda minima. In this study, for the first time, we investigated their anti-NPC effects and further explored the related molecular mechanisms. The effects of both arnicolide C and arnicolide D were tested in NPC cells CNE-1, CNE-2, SUNE-1, HONE1, and C666-1. The results showed that the two compounds inhibited NPC cell viability in a concentration- and time-dependent manner. As the inhibitory effect of arnicolide D was the more pronounced of the two, our following studies focused on this compound. Arnicolide D could induce cell cycle arrest at G(2)/M, and induce cell apoptosis. The molecular mechanism of cell cycle regulation and apoptosis induction was investigated, and the results showed that arnicolide D could downregulate cyclin D3, cdc2, p-PI3K, p-AKT, p-mTOR, and p-STAT3, and upregulate cleaved PARP, cleaved caspase 9, and Bax. Regulation of cyclin B1, cdk6, and Bcl-2 expression by arnicolide D showed dynamic changes according to dose and time. Taken together, arnicolide D modulated the cell cycle, activated the caspase signaling pathway, and inhibited the PI3K/AKT/mTOR and STAT3 signaling pathways. These findings provide a solid base of evidence for arnicolide D as a lead compound for further development, and act as proof for the viability of drug development from traditional Chinese medicines.
ISSN: 1420-3049
DOI: 10.3390/molecules24101908
Rights: © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (
The following publication Liu, R.; Dow Chan, B.; Mok, D. .-W.; Lee, C.-S.; Tai, W. .-S.; Chen, S. Arnicolide D, from the herb Centipeda minima, Is a Therapeutic Candidate against Nasopharyngeal Carcinoma. Molecules 2019, 24, 1908, 15 pages is available at
Appears in Collections:Journal/Magazine Article

Files in This Item:
File Description SizeFormat 
Liu_D_Centipeda_Is.pdf2.8 MBAdobe PDFView/Open
View full-text via PolyU eLinks SFX Query
Show full item record
PIRA download icon_1.1View/Download Contents

Page view(s)

Citations as of Aug 21, 2019


Citations as of Aug 21, 2019

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.